Taiho Oncology, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-34
RECRUITING4
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO70%
Delay Index: of 10 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +38.0 months). See all sponsors →
Open Taiho Oncology, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ASTX660 NCT02503423 |
P1/2 | Active, not recruiting | Solid Tumors; Lymphoma | 253 | 2022-10 (+51 mo) |
| Decitabine and Cedazuridine (ASTX727) NCT04657081 |
P1/2 | Active, not recruiting | Acute Myeloid Leukemia | 101 | 2024-09-30 (+39 mo) |
| Futibatinib NCT05945823 |
P2 | Active, not recruiting | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adenocarcinoma | 53 | 2026-10-01 (+21 mo) |
| FOENIX-CCA4 NCT05727176 |
P2 | Recruiting | Advanced Cholangiocarcinoma; FGFR2 Fusions | 120 | 2026-12 (+18 mo) |
| futibatinib NCT06506955 |
P2/3 | Active, not recruiting | Advanced/Metastatic Cancer | 15 | 2027-04 (+3 mo) |
| REZILIENT3 NCT05973773 |
P3 | Active, not recruiting | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | 285 | 2027-05-27 (+5 mo) |
| Azacitidine NCT04256317 |
P2/3 | Recruiting | Myelodysplastic Syndromes; Acute Myeloid Leukemia | 316 | 2027-11-01 (+55 mo) |
| ASTX727 NCT04093570 |
P2 | Enrolling by invitation | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia | 332 | 2027-12-31 (+81 mo) |
| REZILIENT2 NCT05967689 |
P2 | Recruiting | Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | 220 | 2028-08-31 (+38 mo) |
| REZILIENT4 NCT07128199 |
P3 | Recruiting | Lung Cancer; Adjuvant | 360 | 2029-10-01 |